尼洛替尼或达沙替尼二三线治疗CML的疗效与影响因素
回顾性分析226例一二线TKI治疗失败的CML-CP/AP患者,接受尼洛替尼或达沙替尼二线(183例)或三线(43例)治疗。二线中位随访21个月,CHR率80.4%、CCyR率56.3%、MMR率38.3%,3年PFS和OS分别为78.7%和93.1%;三线中位随访6个月,CHR率95.7%、CCyR率29.3%、MMR率18.6%,2年PFS和OS分别为66.8%和93.8%。前次TKI最佳反应、换药前疾病分期及本次治疗严重血液学毒性影响结局。
要点
- 二线尼洛替尼/达沙替尼治疗CML-CP/AP的3年PFS为78.7%,OS为93.1%。
- 三线治疗CHR率95.7%但CCyR率仅29.3%,2年PFS为66.8%。
- 前次TKI最佳反应<CHR、换药前AP及严重血液学毒性提示不良结局。
核心结论
- 尼洛替尼和达沙替尼作为二三线药物可有效治疗TKI耐药的CML-CP和AP患者。
- 前次TKI治疗期间获得的最佳反应、换药前疾病分期和本次TKI治疗中是否发生≥3级血液学不良反应等因素影响治疗结果。
研究设计与样本
- 回顾性分析2008年1月至2018年11月北京大学人民医院收治的一二线TKI治疗失败并接受尼洛替尼或达沙替尼作为二三线治疗的CML-CP和AP患者资料。
- 共纳入226例患者,其中二线治疗183例,三线治疗43例。
主要发现
- 二线治疗患者中位随访21(1~135)个月,CHR率80.4%,CCyR率56.3%,MMR率38.3%,3年PFS和OS率分别为78.7%和93.1%。
- 二线TKI治疗中,Sokal积分为高危、女性、一线TKI治疗期间获得最佳反应<CHR、诊断CML距转换二线TKI治疗时间≥18个月、二线TKI治疗前为AP/血液学耐药、二线TKI治疗前未检测出BCR-ABL特殊突变、二线治疗中发生≥3级血液学不良反应是获得细胞遗传学或分子学反应或PFS的不利影响因素。
- 三线治疗患者中位随访6(3~129)个月,CHR率95.7%,CCyR率29.3%,MMR率18.6%,2年PFS和OS率分别为66.8%和93.8%。
- 三线TKI治疗中,诊断距一线TKI治疗时间≥6个月、二线TKI治疗期间未获得细胞遗传学反应、诊断距三线TKI治疗时间≥60个月或转换治疗前疾病分期为AP患者获得治疗反应的比例显著降低或预后不良。
临床怎么用
- 对一二线TKI治疗失败的CML-CP/AP患者,尼洛替尼或达沙替尼作为二三线治疗仍可获得较高的血液学反应和一定程度的细胞遗传学/分子学反应。
- 换药前应评估前次TKI最佳反应、疾病分期及BCR-ABL突变状态,以识别可能从二三线TKI治疗中获益较低的患者。
- 治疗中需监测并管理≥3级血液学不良反应,因其与二线TKI治疗不良结局相关。
局限性
- 本研究为单中心回顾性分析,样本量有限(二线183例、三线43例)。
- 三线治疗患者中位随访仅6个月,长期结局需更长时间随访验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To explore the efficacy and prognosis of nilotinib or dasatinib as second- or third-line treatment in patients with chronic myeloid leukemia (CML) in the chronic phase (CP) and accelerated phase (AP) . Methods: From January 2008 to November 2018, the data of CML patients who failed first- or second-line tyrosine kinase inhibitor (TKI) -therapy received nilotinib or dasatinib as second-line and third-line therapy were retrospectively reviewed. Results: A total of 226 patients receiving nilotinib or dastinib as second-line (n=183) and third-line (n=43) therapy were included in this study. With a median follow-up of 21 (range, 1-135) months, the cumulative rates of complete hematological response (CHR) , complete cytogenetic response (CCyR) and major molecular response (MMR) were 80.4%, 56.3%and 38.3%, respectively in those receiving TKI as second-line TKI therapy. The 3-year progression-free survival (PFS) and overall survival (OS) rates were 78.7%and 93.1%, respectively. Multivariate analyses showed that Sokal high risk, female gender, the best response achieved <CHR on the first-line TKI-therapy, the interval from diagnosis to switching to second-line TKI ≥18 months, AP or hematologic failure, or non-specific mutation of BCR-ABL kinase domain before second-line TKI therapy, developing severe hematologic toxicity during the second-line TKI therapy were variables associated with poor responses or outcomes on second-line TKI therapy. With a median follow-up of 6 (range, 3-129) months, the cumulative CHR, CCyR and MMR were 95.7%, 29.3%, and 18.6%, respectively in those receiving the third-line TKI therapy. The 2-year PFS and OS rates were 66.8% and 93.8%, respectively. The patients with an interval from diagnosis to starting TKI ≥6 months, achieving no cytogenetic response on the second-line TKI, the interval from diagnosis to starting second-line TKI ≥60 months, and progression to AP before the third-line TKI therapy had lower probabilities of responses and unfavorable outcomes. Conclusions: The efficacy of dasatinib and nilotinib as second- or third-line TKI-therapy were active in the CML patients with TKI-resistance. The best response achieved on previous TKI-therapy, the disease phase before switching TKI, and the severe hematologic toxicity developing on the current TKI-therapy were associated with the responses and outcomes. 目的: 分析二代酪氨酸激酶抑制剂(TKI)尼洛替尼和达沙替尼作为二三线药物治疗慢性髓性白血病(CML)慢性期(CP)和加速期(AP)患者的治疗反应和预后,以及相关影响因素。 方法: 回顾性分析2008年1月至2018年11月北京大学人民医院收治的一二线TKI治疗失败并接受尼洛替尼或达沙替尼作为二三线治疗的CML-CP和AP患者资料。 结果: 共收集183例尼洛替尼和达沙替尼作为二线治疗和43例尼洛替尼和达沙替尼作为三线治疗的CML-CP或AP患者。二线TKI治疗患者中,中位随访21(1~135)个月,完全血液学反应(CHR)率为80.4%,完全细胞遗传学反应(CCyR)率为56.3%,主要分子学反应(MMR)率为38.3%,3年疾病无进展生存(PFS)和总生存(OS)率分别为78.7%和93.1%。二线TKI治疗中,Sokal积分为高危、女性、一线TKI治疗期间获得最佳反应<CHR、诊断CML距转换二线TKI治疗时间≥18个月、二线TKI治疗前为AP/血液学耐药、二线TKI治疗前未检测出BCR-ABL特殊突变、二线治疗中发生≥3级血液学不良反应是获得细胞遗传学或分子学反应或PFS的不利影响因素。三线TKI治疗患者中,中位随访6(3~129)个月,CHR率为95.7%,CCyR率为29.3%,MMR率为18.6%,2年PFS和OS率分别为66.8%和93.8%。三线TKI治疗中,诊断距一线TKI治疗时间≥6个月、二线TKI治疗期间未获得细胞遗传学反应、诊断距三线TKI治疗时间≥60个月或转换治疗前疾病分期为AP患者获得治疗反应的比例显著降低或预后不良。 结论: 尼洛替尼和达沙替尼作为二三线药物可以有效治疗TKI耐药的CML-CP和AP患者,前次TKI治疗期间获得的最佳反应、换药前疾病分期和本次TKI治疗中是否发生≥3级血液学不良反应等因素影响治疗结果。.
引用
- Yuan T, Lai YY, Qin YZ, et al. [Analysis of the efficacy and influencing factors of nilotinib or dasatinib as second- or third-line treatment in patients with chronic myeloid leukemia in the chronic phase and accelerated phase]. Zhonghua Xue Ye Xue Za Zhi. 2020. PMID: 32135623. doi:10.3760/cma.j.issn.0253-2727.2020.02.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。